leisure time -WSS

leisure time

author：comprehensive 2025-09-03 11:50:48 - browse：82918

Ula Jurkunas, associate director of the cornea service at Mass Eye and Ear, performs the first CALEC surgery. Courtesy Mass Eye and Ear

The first time Phillip Durst saw the big A on the chart, he could hardly believe it. It was the first in a series of letters to check his vision in his left eye. “They keep flipping the chart and it keeps getting smaller and smaller, and I keep identifying the letters — that was huge,” said Durst. “It’s like a miracle.”

A year earlier, in April 2017, Durst had lost sight from that same eye after it was hit by a caustic water treatment solution in a work accident. The damage was so severe that a standard corneal transplant would not resolve it. But in April 2018, he underwent a new, innovative procedure: An eye stem cell transplant led by Ula Jurkunas, the associate director of the cornea service at Mass Eye and Ear in Boston.

Durst, now 51 years old, is the first of four patients who were included in a Phase 1 trial of Cultivated Autologous Limbal Epithelial Cell (CALEC) transplant, the results of which were published Friday in Science Advances. The procedure allowed him to become a suitable candidate for another surgery, the artificial corneal transplant, while rehabilitating his vision — and his life.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： U.S. death rates show how politics are affecting public health

WSS

Activists slam private health insurers over coverage restrictions

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hospitals need to get ahead of regulations on climate change

The cancer drug shortage isn’t new — and neither are the solutions

Should insurance cover cosmetic surgery?

Duchenne breakthrough therapy leaves behind pioneering families

focus

leisure time

Wikipedia

Psychedelics group wrestles with new pharma identity

United colonoscopy coverage change 'may cost lives,' doctors say

How to save PrEP access — and even expand it

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Virginia high school admissions case could be legal follow

Unmasking the 'centricity' illusion in clinical trials

The cancer drug shortage isn’t new — and neither are the solutions

Decentralized clinical trials need collaboration to achieve wider use

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why we need mandatory labeling of GMO products

hotspot

Hollywood unions extend contract negotiations for actors

Cancer drug shortages should be causing more outrage

United colonoscopy coverage change 'may cost lives,' doctors say

Cancer drug shortages should be causing more outrage

Medical students need to learn the potent medicine of empathy

Achieving telehealth equity for people with hearing loss

focus

entertainment

focus

knowledge